Bedaquiline-pretomanid-moxifloxacin-pyrazinamide for drug-sensitive and drug-resistant pulmonary tuberculosis treatment: a phase 2c, open-label, multicentre, partially randomised controlled trial
Cevik, Muge, Thompson, Lindsay C, Upton, Caryn, Rolla, Valéria Cavalcanti, Malahleha, Mookho, Mmbaga, Blandina, Ngubane, Nosipho, Abu Bakar, Zamzurina, Rassool, Mohammed, Variava, Ebrahim, Dawson, Rodney, Staples, Suzanne, Lalloo, Umesh, Louw, Cheryl, Conradie, Francesca, Eristavi, Marika, Samoilova, Anastasia, Skornyakov, Sergey N, Ntinginya, Niyanda Elias, Haraka, Frederick, Praygod, George, Mayanja-Kizza, Harriett, Caoili, Janice, Balanag, Vincent, Dalcolmo, Margareth Pretti, McHugh, Timothy, Hunt, Robert, Solanki, Priya, Bateson, Anna, Crook, Angela M, Fabiane, Stella, Timm, Juliano, Sun, Eugene, Spigelman, Melvin, Sloan, Derek J, Gillespie, Stephen H, Bruinenberg, Paul, Beumont, Maria, Nedelman, Jerry, Li, Mengchun, Zuma-Gwala, Ntokozo, Rajaram, Shakira, Choo, Louise, Wills, Genevive, Betteridge, Matt, Leandra, Leandra, Olugbosi, Morounfolu, Borisov, Sergey
Published in The Lancet infectious diseases (01.09.2024)
Published in The Lancet infectious diseases (01.09.2024)
Get full text
Journal Article